{"id":488,"date":"2020-06-03T21:24:16","date_gmt":"2020-06-03T21:24:16","guid":{"rendered":"http:\/\/www.chinaiplawupdate.com\/?p=488"},"modified":"2021-03-08T05:10:46","modified_gmt":"2021-03-08T05:10:46","slug":"chinese-patent-application-for-coronavirus-vaccine-published","status":"publish","type":"post","link":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/","title":{"rendered":"Chinese Patent Application for Coronavirus Vaccine Published"},"content":{"rendered":"<p>The <a href=\"http:\/\/www.cnipa.gov.cn\/\">China National Intellectual Property Administration<\/a> published on June 2, 2020 what may be the first patent application covering a vaccine for the COVID-19 virus.\u00a0 The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with <a href=\"http:\/\/www.cansinotech.com.cn\/\">CanSinoBIO<\/a>, a Chinese vaccine maker, filed application <a href=\"https:\/\/www.incopat.com\/detail\/init2?formerQuery=3eQEo0gaDThQKXKRZOStZWr4kAd0KKkg&local=zh\">CN202010193587.8<\/a> on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.”\u00a0 The patent application is based on research later <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31208-3\/fulltext\">published in the Lancet<\/a> showing their Ad5 vectored COVID-19 vaccine “is tolerable and immunogenic at 28 days post-vaccination.” The vaccine is the first candidate vaccine to begin<a href=\"http:\/\/newswire.ca\/news-releases\/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19-816213726.html\"> conducting Phase II human clinical trials<\/a>.<!--more--><\/p>\n<p>The patent application claims a polynucleotide, vector of the polynucleotide, adenovirus, and method of manufacturing the adenovirus.\u00a0\u00a0<\/p>\n<p>The unexamined claims follow:<\/p>\n<p>1. A polynucleotide for coding a S protein of the 2019 novel coronavirus is characterized in that the sequence of the polynucleotide is shown as SEQ ID NO: 1.<\/p>\n<p>2. A vector comprising the polynucleotide of claim 1.<\/p>\n<p>3. The vector of claim 2, wherein the vector is pDC316.<\/p>\n<p>4. A human replication-deficient recombinant adenovirus capable of expressing the polynucleotide of claim 1.<\/p>\n<p>5. The recombinant adenovirus of claim 4, wherein the recombinant adenovirus is derived from an admax adenovirus system.<\/p>\n<p>6. The use of the recombinant adenovirus of claims 4 and 5 in the preparation of a vaccine for the prevention of 2019 novel coronavirus.<\/p>\n<p>7. The method of claim 6, wherein the recombinant adenovirus is formulated as an injection, nasal drop, or spray.<\/p>\n<p>8. The use of claim 7, wherein the recombinant adenovirus is prepared as an intramuscular injection.<\/p>\n<p>9. A method of preparing a recombinant adenovirus according to claim 4 or 5, said method comprising the steps of: (1) constructing a shuttle plasmid vector comprising a polynucleotide encoding a 2019 novel coronavirus s protein; (2) transfecting the shuttle plasmid vector and the skeleton plasmid of step (1) into the host cell; (3) culturing the host cell in step (2); (4) harvesting the human replication-deficient recombinant adenovirus released from the cells of step (3); (5) amplifying and culturing the recombinant adenovirus in step (4); (6) purifying the culture product in step (5).<\/p>\n<p>10. The method of claim 9, wherein the vector of step (1) is pDC316.<\/p>\n<p>11. The method of claim 9, wherein the backbone plasmid of step (2) is pBHGlox_E1, 3Cre.<\/p>\n<p>12. The method of claim 9, wherein the cell of step (3) is an hek293 cell.<\/p>\n<p>13. The method of claim 9, wherein the amplification culture method of step (5) is suspension culture.<\/p>\n<p>14. The method of claim 9, wherein the purification method of step (6) is source 30q chromatography.<\/p>\n<p>There is no word yet on whether the application has or will be foreign filed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"excerpt\">The China National Intellectual Property Administration published on June 2, 2020 what may be the first patent application covering a vaccine for the COVID-19 virus.\u00a0 The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with CanSinoBIO, a Chinese vaccine maker, filed application CN202010193587.8 on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.”\u00a0 The patent application is based on research later published in the Lancet showing their Ad5 …<\/p>\n<p class=\"more-link\"><a href=\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\" class=\"button\">Continue Reading<\/a><\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"coauthors":[22],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update\" \/>\n<meta property=\"og:description\" content=\"The China National Intellectual Property Administration published on June 2, 2020 what may be the first patent application covering a vaccine for the COVID-19 virus.\u00a0 The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with CanSinoBIO, a Chinese vaccine maker, filed application CN202010193587.8 on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.”\u00a0 The patent application is based on research later published in the Lancet showing their Ad5 ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\" \/>\n<meta property=\"og:site_name\" content=\"China IP Law Update\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-03T21:24:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-08T05:10:46+00:00\" \/>\n<meta name=\"author\" content=\"Aaron Wininger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aaron Wininger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\"},\"author\":{\"name\":\"Aaron Wininger\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5\"},\"headline\":\"Chinese Patent Application for Coronavirus Vaccine Published\",\"datePublished\":\"2020-06-03T21:24:16+00:00\",\"dateModified\":\"2021-03-08T05:10:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\"},\"wordCount\":410,\"publisher\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\"},\"articleSection\":[\"Patents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\",\"name\":\"Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#website\"},\"datePublished\":\"2020-06-03T21:24:16+00:00\",\"dateModified\":\"2021-03-08T05:10:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.chinaiplawupdate.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chinese Patent Application for Coronavirus Vaccine Published\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#website\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/\",\"name\":\"China IP Law Update\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.chinaiplawupdate.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\",\"name\":\"China IP Law Update\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png\",\"contentUrl\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png\",\"width\":240,\"height\":81,\"caption\":\"China IP Law Update\"},\"image\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5\",\"name\":\"Aaron Wininger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/image\/2a4c57b1fc56e213ed27e140da54c8a1\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg\",\"contentUrl\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg\",\"caption\":\"Aaron Wininger\"},\"description\":\"Aaron Wininger is a Principal and Director of the China Intellectual Property at Schwegman Lundberg & Woessner.\",\"sameAs\":[\"http:\/\/www.chinaiplawupdate.com\/aaron-wininger\/\",\"https:\/\/www.linkedin.com\/in\/aaron-wininger-135113\/\"],\"url\":\"https:\/\/www.chinaiplawupdate.com\/author\/aaron-wininger\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/","og_locale":"en_US","og_type":"article","og_title":"Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update","og_description":"The China National Intellectual Property Administration published on June 2, 2020 what may be the first patent application covering a vaccine for the COVID-19 virus.\u00a0 The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with CanSinoBIO, a Chinese vaccine maker, filed application CN202010193587.8 on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.”\u00a0 The patent application is based on research later published in the Lancet showing their Ad5 ...","og_url":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/","og_site_name":"China IP Law Update","article_published_time":"2020-06-03T21:24:16+00:00","article_modified_time":"2021-03-08T05:10:46+00:00","author":"Aaron Wininger","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Aaron Wininger","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#article","isPartOf":{"@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/"},"author":{"name":"Aaron Wininger","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5"},"headline":"Chinese Patent Application for Coronavirus Vaccine Published","datePublished":"2020-06-03T21:24:16+00:00","dateModified":"2021-03-08T05:10:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/"},"wordCount":410,"publisher":{"@id":"https:\/\/www.chinaiplawupdate.com\/#organization"},"articleSection":["Patents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/","url":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/","name":"Chinese Patent Application for Coronavirus Vaccine Published - China IP Law Update","isPartOf":{"@id":"https:\/\/www.chinaiplawupdate.com\/#website"},"datePublished":"2020-06-03T21:24:16+00:00","dateModified":"2021-03-08T05:10:46+00:00","breadcrumb":{"@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.chinaiplawupdate.com\/2020\/06\/chinese-patent-application-for-coronavirus-vaccine-published\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.chinaiplawupdate.com\/"},{"@type":"ListItem","position":2,"name":"Chinese Patent Application for Coronavirus Vaccine Published"}]},{"@type":"WebSite","@id":"https:\/\/www.chinaiplawupdate.com\/#website","url":"https:\/\/www.chinaiplawupdate.com\/","name":"China IP Law Update","description":"","publisher":{"@id":"https:\/\/www.chinaiplawupdate.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chinaiplawupdate.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.chinaiplawupdate.com\/#organization","name":"China IP Law Update","url":"https:\/\/www.chinaiplawupdate.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png","contentUrl":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png","width":240,"height":81,"caption":"China IP Law Update"},"image":{"@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5","name":"Aaron Wininger","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/image\/2a4c57b1fc56e213ed27e140da54c8a1","url":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg","contentUrl":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg","caption":"Aaron Wininger"},"description":"Aaron Wininger is a Principal and Director of the China Intellectual Property at Schwegman Lundberg & Woessner.","sameAs":["http:\/\/www.chinaiplawupdate.com\/aaron-wininger\/","https:\/\/www.linkedin.com\/in\/aaron-wininger-135113\/"],"url":"https:\/\/www.chinaiplawupdate.com\/author\/aaron-wininger\/"}]}},"co_authors":[4],"_links":{"self":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/488"}],"collection":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/comments?post=488"}],"version-history":[{"count":4,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/488\/revisions"}],"predecessor-version":[{"id":492,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/488\/revisions\/492"}],"wp:attachment":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/media?parent=488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/categories?post=488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/tags?post=488"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/coauthors?post=488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}